Head-to-head · WeighScore
Eve vs TeleClinic
The verdict
Eve takes it — 66/100 to 60.8/100.
Eve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Eve | TeleClinic |
|---|---|---|
| WeighScore | 66/100 | 60.8/100 |
| Grade | C | C |
| Scorecard rank | #210 | #314 |
| Semaglutide | $195/mo (compounded) | $199/mo (compounded) |
| Tirzepatide | $195/mo (compounded) | $299/mo (compounded) |
| Coverage | Coverage not published | 47 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #210 · C
Strengths
- Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
- Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
- LegitScript Certified with a verifiable ID
- Publishes the FDA compounded-medication disclaimer
- Oral sublingual semaglutide offered alongside injectable
Where it loses points
- Full states-served list not disclosed publicly
- 503A pharmacy partner not named, and 503A vs 503B status not specified
- Named medical director / clinical leadership not disclosed
- Corporate legal entity not disclosed
- Governing law / arbitration venue not stated
Graded #314 · C
Strengths
- Names its pharmacy partner — Rush Pharmacy, a licensed 503A compounder — which many compounded-GLP-1 telehealths won't disclose
- LegitScript certified with flat, published monthly pricing, free shipping, and no insurance required
- Broad access: 47 states with US-licensed physicians and transparent cash-pay pricing
Where it loses points
- Compounded semaglutide and tirzepatide only — no brand-name GLP-1 (Wegovy or Zepbound) option
- Headline $139/$219 rates are first-quarter intro prices billed quarterly; ongoing month-to-month is $199/$299
- Not available in California, South Carolina, or New Jersey
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.